So, if you've been prescribed Ozempic for weight loss outside of diabetes care, its considered off-label use
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
These two categories differ significantly in approval standards, clinical evidence, manufacturing oversight, and insurance coverage
And BMI also doesnt factor in body fat distribution or consider other health conditions
If that lawsuit were to succeed, or if Novo Nordisks capacity to produce were to falter, the drugs may end up back on the shortage list
Originally approved by the FDA for the treatment of adult obesity in 2014, the drug received authorisation in 2020 for obesity in adolescents aged 12-17 years old (Mller, Blher, Tschp, DiMarchi)